Navigation Links
Schulman Associates IRB offers oncology-focused review board

CINCINNATI, June 25, 2012 /PRNewswire/ -- The fight against cancer continues to be an ongoing challenge for many patients, their families, healthcare providers and economies worldwide. Although significant progress has been made, many forms of the disease remain a public health issue.

According to PhRMA, American biopharma research companies are testing 981 medicines and vaccines to fight the many types of cancer affecting millions of patients. All of the medicines are either in clinical trials or awaiting review by the Food and Drug Administration (

In response to the recent increases in oncology research conducted in North America, Schulman Associates IRB now offers a weekly Board meeting dedicated to the review of oncology research. The new Board's membership consists of a variety of oncology experts, who were carefully recruited from prestigious, nationally recognized research centers, and specifically selected based on their qualifications. Concentrations include pediatric oncology, radiation oncology, oncology research administration and more. The Schulman Oncology Board will meet weekly beginning July 23 and will be one of the leading oncology Boards in North America.

Oncology Board members will also lend their expertise to Schulman's regular Board meetings, as needed. Additional submission materials are not required to take advantage of the Oncology Board's services. Review turnaround times for the Oncology Board will remain consistent with Schulman's standard, competitive timelines.

"This enhanced Board expertise and dedicated additional Board meeting underscore Schulman's commitment to growth and improvement," said Michael Woods, Schulman's president and CEO. "We are delighted to be able to offer an unsurpassed level of service and expertise to our clients who are working to develop new cancer therapies and diagnostics."

The Oncology Board will review both industry-sponsored research as well as federally funded research. As with Schulman's other Review Boards, the Oncology Board will oversee research conducted at universities, hospital systems, community practices and other research sites.

For more information about the Oncology Board, please contact Stephanie Pyle at

About Schulman Associates IRB
Schulman Associates Institutional Review Board, Inc. ("Schulman") is an independent IRB that has more than 25 years of experience in reviewing research protocols and consent documents to evaluate compliance with relevant regulations and ethical guidelines. As an independent IRB, Schulman is not part of an institution such as an academic medical center or hospital. Schulman can provide IRB services for single and multi-site studies within the United States, Puerto Rico and Canada.  In June 2011, Schulman was awarded full five-year reaccreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP). The Accreditation by AAHRPP demonstrates its commitment to research ethics and human subject protection.

SOURCE Schulman Associates Institutional Review Board, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical to Present at Todays Security Research Associates 8th Annual Growth Conference
2. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
3. Sensus Healthcare and Texas Dermatology Associates at Baylor University Medical Center Announce the Formation of the SRT University™ Comprehensive Education Series for Practitioners, Healthcare Professionals, and Patients
4. San Diego Based Neurosurgeon Offers Groundbreaking Treatment to Restore Function for People Suffering from Mobility Inhibiting Paralysis
5. New Jersey Ophthamologist Now Offers Pelleve Wrinkle Reduction Treatment
6. New Medical Device Study Offers Key Marketing Budget and Staffing Metrics to Promote Effective Use of Resources
7. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Frost & Sullivan Research Preview: Top 20 Telehealth Markets
10. Webcast Alert: Isis Pharmaceuticals Hosts Dr. Sotirios Tsimikas to Review KYNAMRO™ data Presented at the European Atherosclerosis Society 2012 Meeting
11. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
Post Your Comments:
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
Breaking Medicine News(10 mins):